Eton Pharmaceuticals, Inc.

ETON Nasdaq SEC CIK 1710340
Follow Eton Pharmaceuticals Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $57.9M +157.9% vs same quarter last year
Net income $35.2M +1929.2% vs same quarter last year
EPS, diluted $1.06 +1614.3% vs same quarter last year
Operating cash flow $35.2M +193% vs same quarter last year
Revenue by quarter
$11.6M
$17.3M
$18.9M
$22.5M
$21.3M
$24.3M
$37.6M
$57.9M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income9 fiscal years
  • Revenue
  • Net income
−$50M$0$50M$100MFY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$80M−$4.6M
FY24$39M−$3.8M
FY23$31.6M−$936K
FY22$21.3M−$9M
FY21$21.8M−$2M
FY20$39K−$28M
FY19$959K−$18.3M
FY18-−$12.7M
FY17--
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−80000%−60000%−40000%−20000%0%20000%FY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2553.5%−1.1%−5.8%
FY2460%−6.7%−9.8%
FY2366.6%−3.8%−3%
FY2267.4%−38.9%−42.4%
FY2187.1%−6.8%−9%
FY20−1017.9%−69515.4%−71717.9%
FY1952.8%−1939.6%−1910.3%
FY18---
FY17---
Free cash flowOperating cash flow minus capital expenditure
−$30M−$20M−$10M$0$10M$20MFY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25$10.2M
FY24$943K
FY23$6.8M
FY22$4.8M
FY21−$4.7M
FY20−$22.4M
FY19−$19.1M
FY18−$8.4M
FY17-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Eton Pharmaceuticals
  • Healthcare median
−80000%−60000%−40000%−20000%0%FY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearEton PharmaceuticalsHealthcare median
FY25−5.8%−30.6%
FY24−9.8%−47%
FY23−3%−58%
FY22−42.4%−80.4%
FY21−9%−71.8%
FY20−71717.9%−62.2%
FY19−1910.3%−46.2%
FY18-−49.6%
FY17-−45.9%